Carlsmed, Inc. (NASDAQ:CARL) Given Average Recommendation of “Hold” by Brokerages

Shares of Carlsmed, Inc. (NASDAQ:CARL) have been assigned an average rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $21.3333.

CARL has been the topic of a number of recent research reports. Zacks Research upgraded Carlsmed from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 26th. Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. The Goldman Sachs Group reiterated a “buy” rating and set a $20.00 price objective on shares of Carlsmed in a research report on Friday, January 9th. BTIG Research reissued a “buy” rating and issued a $24.00 target price on shares of Carlsmed in a research report on Monday, December 15th. Finally, Weiss Ratings restated a “sell (e-)” rating on shares of Carlsmed in a research note on Monday, December 22nd.

Carlsmed Stock Down 4.5%

Shares of CARL opened at $9.23 on Tuesday. The firm has a market cap of $246.72 million and a P/E ratio of -2.52. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.74 and a current ratio of 8.87. Carlsmed has a 52 week low of $9.00 and a 52 week high of $17.19. The firm’s 50-day simple moving average is $11.94 and its 200 day simple moving average is $12.90.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. Carlsmed had a negative net margin of 58.67% and a negative return on equity of 72.60%. The firm had revenue of $15.16 million during the quarter, compared to the consensus estimate of $15.20 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CARL. Orbimed Advisors LLC bought a new position in shares of Carlsmed during the third quarter worth approximately $16,772,000. Janus Henderson Group PLC grew its position in Carlsmed by 4.4% during the fourth quarter. Janus Henderson Group PLC now owns 1,140,618 shares of the company’s stock worth $14,087,000 after buying an additional 48,081 shares in the last quarter. Vanguard Group Inc. acquired a new stake in Carlsmed during the third quarter worth approximately $3,042,000. TD Waterhouse Canada Inc. increased its stake in Carlsmed by 15.2% during the 4th quarter. TD Waterhouse Canada Inc. now owns 175,405 shares of the company’s stock worth $2,154,000 after acquiring an additional 23,163 shares during the period. Finally, Teacher Retirement System of Texas acquired a new position in Carlsmed in the 3rd quarter valued at $2,343,000.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).